World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2023

D-Index & Metrics

Medicine

D-Index
129
Citations
81429
World Ranking
2540
National Ranking
124

Research.com Recognitions

  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Peter A. Fasching is affiliated with the University of Erlangen-Nuremberg in Germany. Their research spans multiple fields with a strong focus on medicine, particularly oncology and cancer research. They have published extensively in subfields such as pulmonary and respiratory medicine, genetics, and molecular biology.

The scientist's work covers key topics including:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Frequent co-authors collaborating with Peter A. Fasching include:

  • Andreas Schneeweiß
  • Michael Untch
  • Volkmar Müller
  • Matthias W. Beckmann
  • Tanja Fehm

The scientist has contributed to a range of prominent publication venues, often publishing in:

  • Cancer Research
  • Geburtshilfe und Frauenheilkunde
  • Annals of Oncology
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Journal of Clinical Oncology

Among notable recent papers associated with the broader research community and topics related to Fasching's expertise are:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, 2021, New England Journal of Medicine
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses, 2020, Nature Genetics
  • Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials, 2021, The Lancet Oncology
  • Genetic insights into biological mechanisms governing human ovarian ageing, 2021, Nature

Peter A. Fasching's research outputs contribute primarily to understanding the molecular and clinical facets of cancer, with a dominant emphasis on breast cancer therapies and genetic factors implicated in oncological diseases.

Best Publications

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk

    Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

    Celeste Leigh Pearce;Claire Templeman;Mary Anne Rossing;Alice Lee

  • RAD51B in Familial Breast Cancer

    Liisa M. Pelttari;Sofia Khan;Mikko Vuorela;Johanna I. Kiiski

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

    Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch

  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

    Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson

  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

    Leila Dorling;Sara Carvalho;Jamie Allen

  • Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

    Fergus J. Couch;Steven N. Hart;Priyanka Sharma;Amanda Ewart Toland

  • Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

    Brigitte Rack;Christian Schindlbeck;Julia Jückstock;Ulrich Andergassen

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Kyriaki Michailidou;Jonathan Beesley;Sara Lindstrom;Sander Canisius

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

Frequent Co-Authors

Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Graham G. Giles
Graham G. Giles University of Melbourne
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Hiltrud Brauch
Hiltrud Brauch German Cancer Research Center
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Paul D.P. Pharoah
Paul D.P. Pharoah University of Cambridge
Melissa C. Southey
Melissa C. Southey Monash University
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but aren’t sure about becoming a physician, there are several flexible online degree options available. These programs can help you advance in healthcare, management, or nursing—even if you have a busy schedule or need to study remotely.

Healthcare management is a strong alternative to clinical practice. The top cahme accredited mha programs allow you to gain leadership skills for roles in hospitals, clinics, and other healthcare organizations.

For registered nurses wanting to enhance their credentials, the rn to bsn online no clinicals options are ideal. These programs offer academic advancement without the need for additional in-person clinical experience.

If you aim for the highest levels in nursing, consider doctoral pathways. The shortest online dnp program lets you earn a Doctor of Nursing Practice degree far quicker than traditional on-campus routes. Alternatively, if you prefer a less intensive approach, the easiest dnp program online can help you achieve doctorate status with greater flexibility.

Each of these online pathways offers new opportunities for growth in healthcare and supports a variety of professional goals.

Best Scientists Citing Peter A. Fasching

Trending Scientists